Abstract

Aims/hypothesisTranscription factor 7-like 2 (TCF7L2) is a downstream effector of the Wnt/β-catenin signalling pathway implicated in type 2 diabetes risk through genome-wide association studies. Although its expression is critical for adipocyte development, the potential roles of changes in adipose tissue TCF7L2 levels in diabetes risk are poorly defined. Here, we investigated whether forced changes in Tcf7l2 expression in adipocytes affect whole body glucose or lipid metabolism and crosstalk between disease-relevant tissues.MethodsTcf7l2 was selectively ablated in mature adipocytes in C57BL/6J mice using Cre recombinase under Adipoq promoter control to recombine Tcf7l2 alleles floxed at exon 1 (referred to as aTCF7L2 mice). aTCF7L2 mice were fed normal chow or a high-fat diet for 12 weeks. Glucose and insulin sensitivity, as well as beta cell function, were assessed in vivo and in vitro. Levels of circulating NEFA, selected hormones and adipokines were measured using standard assays.ResultsReduced TCF7L2 expression in adipocytes altered glucose tolerance and insulin secretion in male but not in female mice. Thus, on a normal chow diet, male heterozygote knockout mice (aTCF7L2het) exhibited impaired glucose tolerance at 16 weeks (p = 0.03) and increased fat mass (1.4 ± 0.1-fold, p = 0.007) but no changes in insulin secretion. In contrast, male homozygote knockout (aTCF7L2hom) mice displayed normal body weight but impaired oral glucose tolerance at 16 weeks (p = 0.0001). These changes were mechanistically associated with impaired in vitro glucose-stimulated insulin secretion (decreased 0.5 ± 0.1-fold vs control mice, p = 0.02) and decreased levels of the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (0.6 ± 0.1-fold and 0.4 ± 0.1-fold vs control mice, p = 0.04 and p < 0.0001, respectively). Circulating levels of plasma NEFA and fatty acid binding protein 4 were increased by 1.3 ± 0.1-fold and 1.8 ± 0.3-fold vs control mice (p = 0.03 and p = 0.05, respectively). Following exposure to a high-fat diet for 12 weeks, male aTCF7L2hom mice exhibited reduced in vivo glucose-stimulated insulin secretion (0.5 ± 0.1-fold vs control mice, p = 0.02).Conclusions/interpretationLoss of Tcf7l2 gene expression selectively in adipocytes leads to a sexually dimorphic phenotype, with impairments not only in adipocytes, but also in pancreatic islet and enteroendocrine cells in male mice only. Our findings suggest novel roles for adipokines and incretins in the effects of diabetes-associated variants in TCF7L2, and further illuminate the roles of TCF7L2 in glucose homeostasis and diabetes risk.Graphical abstract

Highlights

  • Transcription factor 7-like 2 (TCF7L2) is a member of the high mobility group box family of transcription factors, a downstream effector of the Wnt/β-catenin signalling pathway, and a key regulator of development and cell growth [1]

  • In aTCF7L2het mice, Tcf7l2 mRNA levels were decreased in inguinal adipose tissue by 39.8 ± 13.3%, p = 0.02, while in epididymal white adipose tissue a non-statistically significant reduction (46.3 ± 20.1%; p = 0.09) was observed compared with control mice

  • No changes in Tcf7l2 expression were apparent in liver or pancreatic islets from aTCF7L2het and aTCF7L2hom mice compared with controls (Fig. 1a)

Read more

Summary

Introduction

Transcription factor 7-like 2 (TCF7L2) is a member of the high mobility group box family of transcription factors, a downstream effector of the Wnt/β-catenin signalling pathway, and a key regulator of development and cell growth [1]. TCF7L2 has emerged as an important regulator of energy homeostasis. TCF7L2 is required for normal glucose homeostasis via the maintenance of functional pancreatic beta cell mass and insulin release from the endocrine pancreas [2, 3]. Humans carrying the T risk allele at SNP rs7903146 have elevated proinsulin levels, lowered insulin secretion and impaired responses to the incretin hormone glucagon-like peptide 1 (GLP-1) [7, 8]. While TCF7L2 variants in humans are thought to act via pancreatic beta cell function, the mechanisms driving impaired insulin secretion are still poorly defined [9, 10].

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.